Obesity
Obesity
Search
Introducing Karl and Klara Kidney
Kidney disease and type 2 diabetes are closely linked, and share many of the same risk factors and pathological pathways
Empowering and Upskilling Patient Organizations in the IMETA Region
Boehringer Ingelheim held the first PULSE training programme in Dubai, bringing together over twenty representatives of patient organizations from across India, the Middle East, Turkey, and Africa.
Scleroderma
Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
Immuno-Oncology
We are unlocking the broader possibilities of immuno-oncology, taking cancer on through the power of the body’s immune system.
Patient documentary - From diagnosis to everyday living
Patient documentary - From diagnosis to everyday living
World Heart Day 2021
Cardiovascular diseases, including heart disease, are the leading cause of death and disability worldwide and are closely linked to kidney and metabolic diseases.
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Boehringer Ingelheim Raises Ranking by Two Positions in Access-To-Medicine Index for 2021
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
In 2023, Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increase compared to the previous year.
Industry 40 Innovation in France
Our sites in the Lyon area and Toulouse are investing in the industry of the future.
REACH / GHS / Material safety data sheets
We are continuously working on these topics with the aim to be in compliance with requirements deriving from these legislations.
Cardiovascular Disease
NASH
NASH
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
COVID-19 and Type 2 diabetes Regional experts shed light latest scientific updates and
COVID-19 and Type 2 diabetes: Regional experts shed light on the latest scientific updates and clinical practices in disease management for patient education
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Collaboration Driving Innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Boehringer Ingelheim launches the First Approved Treatment for Idiopathic Pulmonary Fibrosis in Algeria
Nintedanib is the only treatment for Idiopathic Pulmonary Fibrosis approved by the Algerian Ministry of Health
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Horses
Horses
Mareks Disease Poultry Chicken
Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.
Spotlight on GPP
Emmanuelle Clerisme-Beaty, Head of Clinical Development and Medical Affairs, Dermatology, answers some frequently asked questions about GPP.